New share issue of SEK 54 million provides basis for Quiatech to commercialize its products

New share issue of SEK 54 million provides basis for Quiatech to commercialize its products SEB Företagsinvest, Scandinavian Life Science Venture, Stiftelsen Industrifonden and InnovationsKapital invest SEK 54 million in Quiatech. Quiatech will use the proceeds from the new issue mainly to finalize its product development, as well as to commercialize its products. Founded in February 2000, Quiatech is focusing on developing technologies for genetic analysis, molecular diagnostics, and gene-based therapeutics. Its products are based on technologies and patents developed by Associate Professor Marek Kwiatkowski of the Rudbeck Laboratory at Uppsala University, Sweden. Torbjörn Petterson, CEO of Quiatech, says: "The strengthened financial position enables us to more powerfully build on the foundation that we established during the last year. We now have the financial base for a commercialization of Quiatech's products." Björn Österlund, SEB Företagsinvest, comments: "Quiatech is a very exciting company active in a high-growth area. The company holds several unique technologies, which we are convinced will create a strong interest in the market. Therefore, we are very pleased to invest in Quiatech in this exciting phase and we have high expectations on the forthcoming commercialization." Enskilda Securities has been financial advisor to Quiatech in connection with the capital raising. Quiatech AB The Board of Directors For further information, please contact: Torbjörn Pettersson, CEO Quiatech Tel: +46 18 57 23 80 Mobile: +46 706 40 48 96 torbjorn.pettersson@quiatech.com www.quiatech.com ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2003/05/08/20030508BIT00430/wkr0001.doc http://www.waymaker.net/bitonline/2003/05/08/20030508BIT00430/wkr0002.pdf